Loading ...
Sorry, an error occurred while loading the content.

CRF: Treatment for IBS/Info

Expand Messages
  • doug rausch
    Hi Everyone, I thought this would be of some interest to you all. Cynthia, Taffy, Samuel Tummy trouble? Try taming it with peppermint oil. If you re bothered
    Message 1 of 1 , May 1 5:59 AM
    • 0 Attachment
      Hi Everyone,

      I thought this would be of some interest to you all.

      Cynthia, Taffy, Samuel

      Tummy trouble? Try taming it with peppermint oil.

      If you're bothered by irritable bowel syndrome (IBS), which affects 20%
      of Americans--twice as many women as men--give peppermint oil a try.
      Long considered a folk remedy, several studies have shown that IBS
      sufferers who took peppermint oil capsules reduced their symptoms
      significantly compared to patients who took a placebo. Researchers
      believe the oil relaxes the smooth muscle in the lining of the
      intestine, which reduces muscle spasms.

      The recommended dose is 90 milligrams three times per day, preferably
      with a meal. Because peppermint oil can trigger acid reflux, make sure
      that you take the coated-capsule form. This will reduce your chances of
      getting heartburn.


      Irritable bowel syndrome (IBS) is a condition marked by alternating
      diarrhea and constipation, pain, bloating, and an unnerving sense of
      urgency when nature calls. IBS diagnosis can be frustrating, generally
      coming only after other problems, such as cancer and colon obstruction,
      have been ruled out. Because the condition is exacerbated by stress,
      doctors used to routinely dismiss it as psychological. Although many
      cases are mild, the discomfort of IBS and the fear of humiliation can
      keep sufferers housebound. After colds, IBS is the second most common
      reason for missed work in the U.S.

      Enteric-coated peppermint-oil capsules in the treatment of irritable
      bowel syndrome: a prospective, randomized trial.

      Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK
      Department of Internal Medicine, Taichung Veterans
      General Hospital, Taiwan.

      To determine the efficacy and tolerability of an enteric-coated
      peppermint-oil formulation (Colpermin), we conducted a prospective,
      randomized, double-blind, placebo-controlled clinical study in 110
      outpatients (66 men/44 women; 18-70 years of age) with symptoms of
      irritable bowel syndrome. Patients took one capsule (Colpermin or
      placebo) three to four times daily, 15-30 min before meals, for 1 month.
      Fifty-two patients on Colpermin and 49 on placebo completed the study.
      Forty-one patients on Colpermin (79%) experienced an alleviation of the
      severity of abdominal pain (29 were pain-free); 43 (83%) had less
      abdominal distension, 43 (83%) had reduced stool frequency, 38 (73%) had
      fewer borborygmi, and 41 (79%) less flatulence. Corresponding figures
      for the placebo group were: 21 patients (43%) with reduced pain (4 were
      pain-free), 14 (29%) with reduced distension, 16 (32%) with reduced
      stool frequency, 15 (31%) with fewer borborygmi, and 11 (22%) with less
      flatulence. Symptom improvements after Colpermin were significantly
      better than after placebo (P < 0.05; Mann-Whitney U-test). One patient
      on Colpermin experienced heartburn (because of chewing the capsules) and
      one developed a mild transient skin rash. There were no significant
      changes in liver function test results. Thus, in this trial, Colpermin
      was effective and well tolerated.

      Publication Types:
      Clinical trial
      Randomized controlled trial
      PMID: 9430014, UI: 98091849


      Effects of peppermint oil and caraway oil on gastroduodenal motility.

      Micklefield GH, Greving I, May B
      Department of Internal Medicine,
      Ferdinand-Sauerbruch-Klinikum, University Hospital Witten/Herdecke,
      Teaching Hospital of the Heinrich-Heine-University/Dusseldorf,
      Arrenberger Str. 20, 42117 Wuppertal, Germany.

      The effect of enteric-coated (Enteroplant) and non-enteric-coated
      preparations containing a peppermint-caraway oil combination with 90 mg
      peppermint oil and 50 mg caraway oil was studied on gastroduodenal
      motility with stationary manometry in six healthy volunteers. The
      results showed that: (1) both enteric-coated and non-enteric-coated
      preparations have effects on the migrating motor complex (MMC); (2)
      mainly a decrease in the number of contractions and contraction
      amplitudes is seen during the various phases of the MMC; (3)
      non-enteric-coated preparations have their effects mainly during the
      first MMC after administration; (4) enteric-coated preparations have
      their effects temporally delayed during the second MMC after
      administration. In conclusion, enteric-coated and non-enteric-coated
      peppermint-caraway oil combinations are safe preparations, acting
      locally to cause smooth muscle relaxation. Copyright 2000 John Wiley &
      Sons, Ltd.

      Publication Types:
      Clinical trial
      Controlled clinical trial
      PMID: 10641042, UI: 20109240


      [Peppermint oil-caraway oil fixed combination in non-ulcer
      dyspepsia--comparison of the effects of enteric preparations].

      [Article in German]
      Freise J, Kohler S
      Evangelisches Krankenhaus, Muhlheim/Ruhr, Germany.

      223 patients with non-ulcer dyspepsia (dysmotility type dyspepsia or
      essential/idiopathic dyspepsia, also in combination with irritable bowel
      syndrome) were included in a prospective, randomised, reference- and
      double-blind controlled multicentre trial to compare two different
      preparations of a fixed combination of peppermint oil and caraway oil.
      The aim of the trial was to evaluate the equivalence of the efficacy and
      tolerability of these two preparations. The test formulation consisted
      of the drug combination in an enteric coated capsule containing 90 mg
      peppermint oil and 50 mg caraway oil, while an enteric soluble
      formulation containing 36 mg peppermint oil and 20 mg caraway oil was
      used as the reference. The main target item defined was the "difference
      in pain intensity between the beginning and the end of therapy",
      measured by the patient on a visual analogue scale (0 = no pain, 10 =
      extremely strong pain). In 213 patients (n = 108 on the test
      preparation, n = 105 on the reference preparation) with mean pain
      intensity baseline measurements of 6.1 points in the test preparation
      group and 5.9 points in the reference group a statistically significant
      decline in pain intensity was observed in the two groups
      (-3.6 resP. -3.3 points; p < 0.001; two-sided one-sample t-test).
      Equivalent efficacy of both preparations was demonstrated (p < 0.001;
      one-sided t-test for equivalence). With respect to concomitant
      variables, the results in both groups were also similar. Regarding "pain
      frequency", the efficacy of the test preparation was significantly
      better (p = 0.04; two-sided t-test for difference). Both preparations
      were well tolerated. Despite the higher dose, the adverse event
      "eructation with peppermint taste" was less frequent in the group
      treated with the test formulation, due to the enteric coated capsule
      preparation.

      Publication Types:
      Clinical trial
      Multicenter study
      Randomized controlled trial
      PMID: 10192108, UI: 99207832

      This is the only link I could find, your will have to do a search
      there to find these articles.
      site at http://www.ncbi.nlm.nih.gov
    Your message has been successfully submitted and would be delivered to recipients shortly.